Description

ALGREAT 180 MG

Indications

ALGREAT 180 MG is primarily indicated for the treatment of allergic rhinitis, a condition characterized by inflammation of the nasal mucosa due to allergens. It is also used in the management of chronic urticaria, a skin condition marked by the presence of hives. The active ingredient in ALGREAT, bilastine, is effective in alleviating symptoms such as sneezing, itchy nose, runny nose, and itchy or watery eyes, making it a valuable option for patients suffering from these allergic conditions.

Mechanism of Action

ALGREAT contains bilastine, a second-generation antihistamine. Its mechanism of action involves the selective antagonism of peripheral H1 receptors, which are responsible for mediating the effects of histamine in allergic responses. By blocking these receptors, bilastine effectively reduces the symptoms associated with allergic reactions. Unlike first-generation antihistamines, bilastine has minimal sedative effects, making it suitable for individuals who require relief from allergy symptoms without the drowsiness commonly associated with older antihistamines.

Pharmacological Properties

Bilastine exhibits a rapid onset of action, typically within one hour of administration, with a duration of effect lasting up to 24 hours. It is well absorbed in the gastrointestinal tract, with peak plasma concentrations reached approximately 1.5 hours after oral intake. The drug has a high bioavailability of around 61% and is extensively metabolized in the liver, primarily through the cytochrome P450 system. Bilastine is excreted mainly through urine and feces, with a half-life of approximately 14 to 17 hours, allowing for once-daily dosing in most cases.

Contraindications

ALGREAT 180 MG is contraindicated in individuals with hypersensitivity to bilastine or any of the excipients in the formulation. It should not be used in patients with severe renal impairment, as the elimination of the drug may be significantly affected. Additionally, caution is advised when considering the use of ALGREAT in patients with a history of cardiovascular disease, as antihistamines can occasionally lead to tachycardia or other cardiovascular effects.

Side Effects

While ALGREAT is generally well tolerated, some patients may experience side effects. Commonly reported adverse reactions include headache, drowsiness, fatigue, and gastrointestinal disturbances such as nausea. Serious side effects are rare but may include allergic reactions, such as anaphylaxis, and severe skin reactions. Patients are advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of ALGREAT 180 MG for adults and children over the age of 12 is one tablet taken orally once daily. It is advisable to take the medication on an empty stomach, at least one hour before or two hours after a meal, to enhance absorption. For children aged between 6 and 11 years, a lower dose may be recommended based on the physician’s discretion. It is important not to exceed the recommended dosage to minimize the risk of side effects.

Interactions

ALGREAT may interact with other medications, particularly those that are metabolized by the liver. Co-administration with strong inhibitors of cytochrome P450 enzymes, especially CYP3A4, may increase the plasma concentration of bilastine, leading to an increased risk of adverse effects. Alcohol and other central nervous system depressants may enhance the sedative effects of bilastine, although it is less sedating than first-generation antihistamines. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before starting treatment with ALGREAT, patients should be evaluated for any pre-existing medical conditions that may contraindicate its use. Special caution is warranted in elderly patients, as they may be more susceptible to the side effects of antihistamines. Pregnant and breastfeeding women should consult their healthcare provider before using ALGREAT, as the safety of bilastine during pregnancy and lactation has not been fully established. Patients with a history of seizures or those taking medications that may lower the seizure threshold should also exercise caution.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of bilastine in treating allergic rhinitis and chronic urticaria. A randomized, double-blind, placebo-controlled trial involving patients with allergic rhinitis showed that bilastine significantly reduced nasal and ocular symptoms compared to placebo, with a favorable safety profile. Another study focusing on chronic urticaria found that bilastine effectively reduced the severity and frequency of hives, improving the quality of life for patients. These studies underline the therapeutic benefits of ALGREAT in managing allergic conditions.

Conclusion

ALGREAT 180 MG is a well-established antihistamine that provides effective relief from the symptoms of allergic rhinitis and chronic urticaria. Its favorable pharmacological properties, including rapid onset and prolonged duration of action, make it a suitable choice for patients seeking non-sedating allergy relief. However, as with any medication, it is essential for patients to use ALGREAT responsibly and under the guidance of a healthcare professional to ensure safety and efficacy.